Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters XBridge Premier GTx BEH SEC columns doubles the speed of measuring the potency and safety of AAVs. Combining the columns with light scattering technologies from its Wyatt Technology portfolio deepens the level of information acquired from a single experiment and optimizes the manufacturing of these novel gene delivery vehicles.

Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications
The new Waters™ XBridge™ Premier GTx BEH™ SEC columns are aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. They are ideal for process development, formulation studies, regulatory filing support, along with ongoing process monitoring as well as quality control. Image Credit: Waters Corporation

"We are witnessing a revolution in medicine thanks to gene therapies like AAVs," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation. "A small quantity of a gene therapy, such as one of the best-selling eye treatments, can retail for more than $400,000 per eye. This makes it imperative that process and formulation development tests measure multiple attributes of the drug at once while consuming as little of it as possible. It's why Waters' low adsorption, high-efficiency XBridge Premier GTx BEH SEC columns are such a good choice for process development, formulation studies, regulatory filing support, along with ongoing process monitoring as well as quality control."

Avid Bioservices (Tustin, California) received early access to the XBridge Premier GTx columns.

The XBridge Premier GTx BEH SEC columns significantly widened the dynamic range of our SEC platform method for AAV aggregate analysis. It is now possible to analyze AAV aggregates from small amounts of sample with an HPLC method that is up to five times faster than conventional SEC methods for this application. This will help us expedite study timelines and reduce overall costs."

Kilian Witzel, Senior Scientist, Analytical Development Viral Vectors, Avid Bioservices, Inc

AAVs are modified viruses made in bioreactors by living cells and are the number one vehicle for carrying therapeutic genes into human cells. Waters scientists have developed a fast and efficient multi-attribute quantification method of characterizing AAVs that features the following Waters products:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Waters Corporation. (2024, March 29). Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications. AZoLifeSciences. Retrieved on May 30, 2024 from https://www.azolifesciences.com/news/20230824/Waters-Launches-XBridge-Premier-GTx-BEH-SEC-Columns-for-Gene-Therapy-Applications.aspx.

  • MLA

    Waters Corporation. "Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications". AZoLifeSciences. 30 May 2024. <https://www.azolifesciences.com/news/20230824/Waters-Launches-XBridge-Premier-GTx-BEH-SEC-Columns-for-Gene-Therapy-Applications.aspx>.

  • Chicago

    Waters Corporation. "Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications". AZoLifeSciences. https://www.azolifesciences.com/news/20230824/Waters-Launches-XBridge-Premier-GTx-BEH-SEC-Columns-for-Gene-Therapy-Applications.aspx. (accessed May 30, 2024).

  • Harvard

    Waters Corporation. 2024. Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications. AZoLifeSciences, viewed 30 May 2024, https://www.azolifesciences.com/news/20230824/Waters-Launches-XBridge-Premier-GTx-BEH-SEC-Columns-for-Gene-Therapy-Applications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.